A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer.

Trial Profile

A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Valproic acid (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 17 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top